<DOC>
	<DOCNO>NCT00044668</DOCNO>
	<brief_summary>This multi-center , open-label study design examine effect long-term glucose control safety AC2993 patient type 2 diabetes treat metformin , sulfonylurea , metformin sulfonylurea combination .</brief_summary>
	<brief_title>Evaluation Effect Glucose Control Safety AC2993 Patients With Type 2 Diabetes Treated With Metformin , Sulfonylurea , Metformin Sulfonylurea Combination</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects type 2 diabetes Treated least 3 month prior screen either metformin , sulfonylurea , metformin sulfonylurea combination BMI 2545 kg/m^2 HbA1c 7.5 % 12.0 % , inclusive Treated oral antidiabetic agent metformin sulfonylurea within 3 month screen Patients previously treat AC2993 Patients presently treat insulin</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>exendin-4</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>